Brian Rosenberger insider trades: Zynerba Pharmaceuticals (ZYNE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Brian reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 13, 2023 | ZYNE | ↓ Sell | 6,411 | $1.33 | $8K | Direct | Sep 14, 2023 (1d) |
| Jan 23, 2023 | ZYNE | ↓ Sell | 12,663 | $0.60 | $8K | Direct | Jan 25, 2023 (2d) |
| Jul 19, 2022 | ZYNE | ↓ Sell | 4,289 | $1.10 | $5K | Direct | Jul 20, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Brian Rosenberger's insider trades
Brian Rosenberger is VP, Commercial & Business Dev. at Zynerba Pharmaceuticals (ZYNE). Since Jul 19, 2022, Brian has reported no open-market purchases and 3 sales worth $21K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (12 filings), shares withheld for taxes (2 filings), other transactions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZYNE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.